0
     

Report Added
Report already added
Asia-Pacific Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Asia-Pacific Generics Market Summary, Competitive Analysis and Forecast, 2017-2026

Summary

Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The Asia-Pacific generics market had total revenues of $148.9bn in 2021, representing a compound annual growth rate (CAGR) of 6% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 2.2% between 2016 and 2021, to reach a total of 86.1 % in 2021.
- Growth in the market was primarily driven by growth in China and India. In the Chinese market, an aging population alongside increased awareness over healthcare has led to strong growth for generics.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Asia-Pacific
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the Asia-Pacific generics market by value in 2021?
- What will be the size of the Asia-Pacific generics market in 2026?
- What factors are affecting the strength of competition in the Asia-Pacific generics market?
- How has the market performed over the last five years?
- What are the main segments that make up Asia-Pacific's generics market?

Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How did the COVID-19 pandemic impact leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Sun Pharmaceutical Industries Ltd
8.4. Pfizer Inc.
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

List of Tables
Table 1: Asia-Pacific generics market value: $ billion, 2016-21
Table 2: Asia-Pacific generics market volume: %, 2016-21
Table 3: Asia-Pacific generics market geography segmentation: $ billion, 2021
Table 4: Asia-Pacific generics market value forecast: $ billion, 2021-26
Table 5: Asia-Pacific generics market volume forecast: %, 2021-26
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 12: Viatris Inc.: Key Employees Continued
Table 13: Sun Pharmaceutical Industries Ltd: key facts
Table 14: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 15: Sun Pharmaceutical Industries Ltd: Key Employees
Table 16: Sun Pharmaceutical Industries Ltd: Key Employees Continued
Table 17: Pfizer Inc.: key facts
Table 18: Pfizer Inc.: Annual Financial Ratios
Table 19: Pfizer Inc.: Key Employees
Table 20: Pfizer Inc.: Key Employees Continued
Table 21: Asia-Pacific exchange rate, 2017-21

List of Figures
Figure 1: Asia-Pacific generics market value: $ billion, 2016-21
Figure 2: Asia-Pacific generics market volume: %, 2016-21
Figure 3: Asia-Pacific generics market geography segmentation: % share, by value, 2021
Figure 4: Asia-Pacific generics market value forecast: $ billion, 2021-26
Figure 5: Asia-Pacific generics market volume forecast: %, 2021-26
Figure 6: Forces driving competition in the generics market in Asia-Pacific, 2021
Figure 7: Drivers of buyer power in the generics market in Asia-Pacific, 2021
Figure 8: Drivers of supplier power in the generics market in Asia-Pacific, 2021
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Asia-Pacific, 2021
Figure 10: Factors influencing the threat of substitutes in the generics market in Asia-Pacific, 2021
Figure 11: Drivers of degree of rivalry in the generics market in Asia-Pacific, 2021

Report Title: Asia-Pacific Generics Market Summary, Competitive Analysis and Forecast, 2017-2026


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Vietnam Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Venezuela Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for US Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Uruguay Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for United Arab Emirates Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2023 What's Next for Ukraine Diagnostics Market?--2022 Supplier Shares and Strategies, 2022-2027 Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM